[ad_1]
BRASÍLIA – In response to a request for information made by the scholarship prosecutor Ailton Benedito, of the Federal Public Ministry of Goiás, the Brazilian Society of Infectious Diseases (SBI) sent a list of 44 scientific studies, also accompanied by six documents with guidelines for international organizations, which demonstrate the absence of scientific evidence in the use of any drug in the early treatment of Covid-19, including chloroquine, which is usually defended by President Jair Bolsonaro.
Read More: Switzerland is the first country to authorize the standard use of the Pfizer vaccine against Covid-19
The prosecutor had asked the SBI for clarification after the entity published a technical note warning against the use of chloroquine and other drugs in the “early treatment” against the new coronavirus.
In his social networks, Ailton Benedito usually defends the use of chloroquine, has criticized the mandatory vaccination against Covid-19, speaks out against the practice of confinement and refers ironically to a phrase that was used by the former Minister of Health. Luiz Henrique Mandetta. “The ‘science, science, science!’ has yet to show evidence that Covid-19 respects the lockdown, “Benedito wrote on Friday on a social network.
In response to the prosecutor’s request, SBI sent him a 43-page letter presenting scientific research on the treatment of Covid-19. In the material, the SBI listed 11 scientific studies on the use of chloroquine, which concluded that there was no efficacy for treating the disease.
Do the test: What’s your place in the vaccine line?
The SBI also said that the Infectious Diseases Society of the United States (IDSA) has issued guidelines advising against the use of chloroquine and hydroxychloroquine.
“One of the randomized clinical studies found that individuals who received hydroxychloroquine (HCQ) took longer to be discharged from the hospital (16 days versus 13 days) and were less likely to be discharged alive within 28 days of discharge. initiation of treatment. group of patients who received HCQ and were not on mechanical ventilation at the beginning of the study were more likely to progress to the need for mechanical ventilation throughout the study.4 Four randomized clinical studies demonstrated that treatment with HCQ can increase the risk of adverse events, including prolongation of the QT interval and cardiac arrhythmias ”, explained the entity.
Still in the letter, the SBI reports that the National Institutes of Health, research centers that make up the biomedical research agency of the US government, published guidelines against the use of chloroquine, both in hospitalized and outpatients.
The SBI also presents studies showing the ineffectiveness of other drugs, such as ivermectin, azithromycin, dexamethasone, and nitazoxanide.
The references used by the Ministry of Health are contested
Also questioned by the prosecutor if the information note of the Brazilian Ministry of Health that recommended the use of chloroquine was not scientifically valid, the SBI made a detailed analysis of all the bibliographic references used by the ministry.
He noted, for example, that 33 citations from the bibliographic reference consist of publications that do not evaluate the clinical efficacy of drug treatment in patients with Covid-19. A further 12 articles were not peer-reviewed and it was recommended that they should not serve as a guide to guide clinical practice.
Another ten bibliographic citations from the Ministry of Health were references to medical entities that were not directly related to the Covid-19 studies, such as the Brazilian Federation of Gynecology and Obstetrics Associations and the Brazilian Association of Nutrology. In addition, the Ministry of Health made five summons to institutions that came to guide the use of chloroquine and they have already returned.
At the end of the letter, the SBI affirms that the information note produced by the entity, which advises against the use of chloroquine, has the support and agreement of all the former presidents of the SBI alive and of the presidents of the SBI in each Brazilian state. The document is signed by the president of the SBI, Clóvis Arns da Cunha, and by the lawyer Adamares Rocha de Paiva Coutinho.
